Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Decompensation of Pulmonary Hypertension (PROPULS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03926572
Recruitment Status : Recruiting
First Posted : April 24, 2019
Last Update Posted : July 2, 2020
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The main objective of this study is to analyze the survival of a cohort of patients admitted for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary hypertension and to establish the prognostic value of biomarkers.

Condition or disease Intervention/treatment Phase
Hypertension, Pulmonary Biomarkers Other: A biobank will be created from blood samples taken at admission, days 3 and days 7 Not Applicable

Detailed Description:
It is planned to include 150 patients over a two-year period. The primary endpoint is a composite endpoint including death, circulatory assistance or emergency transplantation within 90 days following admission to intensive care unit. Patients will be treated according to the usual practice. A biobank will be created from blood samples taken at admission, days 3 and days 7. Prognostic value of pre-selected biomarkers will be analyzed and a proteomic analysis will be performed in order to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual monitoring parameters that will be collected during follow-up (clinical, echocardiographic and haemodynamic parameters). In a second step, it will establish, using a dynamic model, the best combinations of parameters allowing to best assessment of prognosis of patients suffering from PH and hospitalized for acute right ventricular failure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: patients admitted for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary hypertension with samples of blood samples taken at admission, days 3 and 7 in the context of this clinical study
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Pronostic Study of Biomarkers in Acute Decompensation of Pulmonary Hypertension
Actual Study Start Date : September 19, 2019
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : December 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Patients with Pulmonary arterial hypertension
Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
Other: A biobank will be created from blood samples taken at admission, days 3 and days 7
A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)




Primary Outcome Measures :
  1. time to death, circulatory assistance or emergency transplantation within 90 days following admission to intensive care unit [ Time Frame: 90 days ]
    The primary endpoint is a composite endpoint including death, circulatory assistance or emergency transplantation within 90 days following admission to intensive care unit


Secondary Outcome Measures :
  1. Survival time without graft or circulatory assistance [ Time Frame: 1 month ]
    Survival without transplantation or circulatory assitance at 1 month

  2. Survival time without transplantation or circulatory assitance [ Time Frame: 12 months ]
    Survival ithout transplantation or circulatory assitance at 12 month



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients over 18 years
  • Diagnosis of Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
  • Patients admitted in intensive care unit for acute decompensation of pulmonary hypertension requiring intravenous diuretic therapy ± use of inotropes or vasopressors.
  • Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures

Exclusion Criteria:

  • Patients with post-capillary pulmonary hypertension
  • Patients with pulmonary hypertension associated with chronic respiratory disease
  • Patients with pulmonary hypertension with unclear/or multifactorial mechanisms
  • Patients with operable chronic thromboembolic pulmonary hypertension
  • Shock due to another cause than acute decompensation of pulmonary hypertension
  • Pregnant women, or breast feeding women
  • Adult protected person
  • Person deprived of liberty
  • Person admitted without consent
  • Pregnant or breastfeeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03926572


Contacts
Layout table for location contacts
Contact: SAVALE Laurent, MD, PhD 01 45 21 79 74 laurent.savale@aphp.fr

Locations
Layout table for location information
France
SAVALE Laurent Recruiting
Le Kremlin-Bicêtre, France, 94270
Contact: SAVALE Laurent, PHD    01 45 21 79 74    laurent.savale@aphp.fr   
Contact: SAVALE Laurent         
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Study Chair: SAVALE Laurent, MD, PhD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03926572    
Other Study ID Numbers: APHP180273
First Posted: April 24, 2019    Key Record Dates
Last Update Posted: July 2, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Hypertension
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases